ezetimibe + rosuvastatin + amlodipine + valsartan

This is a **fixed-dose oral combination drug** composed of four well-established small molecule agents: - **Ezetimibe** (a cholesterol absorption inhibitor that blocks NPC1L1-mediated absorption of cholesterol in the small intestine), - **Rosuvastatin** (a statin that inhibits HMG-CoA reductase to reduce endogenous cholesterol biosynthesis), - **Amlodipine** (a dihydropyridine calcium channel blocker that inhibits L-type calcium channels, reducing vascular smooth muscle contraction and thereby lowering blood pressure), and - **Valsartan** (an angiotensin II receptor blocker/ARB that selectively antagonizes the angiotensin II type 1 receptor, promoting vasodilation and reducing blood pressure). The combination is intended for the **simultaneous treatment of hypercholesterolemia and hypertension**, addressing cardiovascular risk factors commonly co-occurring in patients with metabolic syndrome or cardiovascular disease. Such combinations are developed to enhance adherence and simplify therapy regimens for patients requiring multiple agents[1]. No unique international brand appears widely established for this exact four-drug combination; the fixed-dose combinations containing similar ingredients (such as telmisartan instead of valsartan, or omitting one of the four drugs) are in late-stage development and clinical evaluation, primarily in East Asia.

Brand names

Durozet-Q

Other names

ID14009ID-14009ID 14009